MAPK3 and non-small cell lung carcinoma: According to our previous study, MTE restores gefitinib sensitivity in the resistant NSCLC cells and the mechanisms may be partially due to the down-regulation of PI3K/Akt/mTOR and ERK1/2 and inhibition of c-Met phosphorylation [20].